New approaches to mucosal immunization

Advances in Experimental Medicine and Biology

Volumn 473, Issue , 2000, Pages 319-337

  Cárdenas Freytag, Lucía ^a   Cheng, Elly ^a   Mirza, Aysha ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; ESCHERICHIA COLI ENTEROTOXIN; IMMUNOLOGICAL ADJUVANT; IMMUNOLOGICAL ADJUVANT LT(R192G); UNCLASSIFIED DRUG;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; BIODEGRADATION; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; GENETIC TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC PLANT; VACCINATION; VETERINARY MEDICINE;

ADENOSINE DIPHOSPHATE RIBOSE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; BACTERIAL TOXINS; BACTERIAL VACCINES; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; FUNGAL VACCINES; HUMANS; IMMUNITY, MUCOSAL; IMMUNIZATION; VIRAL VACCINES;

ANIMALIA; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

EID: 0034464418     PISSN: 00652598     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. The importance of local mucosal HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12
2. IL-12 is an effective adjuvant for induction of mucosal immunity
3. An experimental prime-boost regimen leading to HIV type 1-specific mucosal and systemic immunity in BALB/c mice
4. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge
5. Site-specific mutagenesis of the catalytic subunit of cholera toxin: Substituting lysine for arginine 7 causes loss of activity
6. Development of mucosal protection against the heat-stable entero-toxin (ST) of Escherichia coli by oral immunization with a genetic fusion delivered by a bacterial vector
7. Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis
8. The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT)
9. LT(R192G), a non-toxic mutant of the heat-labile enterotoxin of Escherichia coli elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp
10. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens
11. Role of GM1 binding in the mucosal immunogenicity and adjuvant activity of the Escherichia coli heat-labile enterotoxin and its B subunit
12. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant
13. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity
14. Use of Escherichia coli Heat-labile Enterotoxin as an Oral Adjuvant
15. Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes
16. Common features of the NAD-binding and catalytic site of ADP-ribosylating toxins
17. Poly(lactide-co-glycolide) microencapsulation of vaccines for mucosal immunization
18. Cholera toxin and its subunits as potential oral adjuvants
19. Regulation of small intestinal ion transport by cyclic nucleotides and calcium
20. Gram-positive commensal bacteria for mucosal vaccine delivery
21. Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit
22. Bacterial toxins as mucosal adjuvants
23. Comparative antibody responses and protection in mice immunized by oral or parenteral routes with influenza virus subunit antigens in aqueous form or incorporated into ISCOMs
24. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity
25. Oral immunization with a recombinant bacterial antigen produced in transgenic plants
26. Inactivation of the Escherichia coli heat-labile enterotoxin by in vitro mutagenesis of the A-subunit gene
27. Construction and characterization of recombinant Vibrio_cholerae strains producing inactive cholera toxin analogs
28. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin
29. Induction of systemic immune responses to measles virus synthetic peptides administered intranasally
30. Heat-labile enterotoxin from E. coli as an adjuvant for oral influenza vaccination
31. Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine
32. Mutants of Escherichia coli heat-labile enterotoxin as an adjuvant for nasal influenza vaccine
33. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi
34. Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis
35. Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes
36. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development
37. Lymphotactin acts as an innate mucosal adjuvant
38. Effect of site-directed mutagenic alterations on ADP-ribosyltransferase activity of the A subunit of Escherichia coli heat-labile enterotoxin
39. Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines
40. Proteosomes, emulsomes, and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gpl60 in mice: Induction of serum intestinal, vaginal, and lung IgA and IgG
41. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity
42. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice
43. Mutation of a buried residue causes loss of activity but no conformational change in the heat-labile enterotoxin of Escherichia coli
44. Liposomes and conjugate vaccines for antigen delivery and induction of mucosal immune responses
45. Immune responses induced by administration of encapsidated poliovirus replicons which express HIV-1 gag and envelope proteins
46. Poliovirus replicons as a vector for mucosal vaccines
47. Recombinant viruses as vectors for mucosal immunity
48. Interaction of ADP-ribosylation factor with Escherichia coli enterotoxin that contains an inactivating lysine 112 substitution
49. Mucosal administration of a chimera composed of Pseudomonas exotoxin and the gpl20 V3 loop sequence of HIV-1 induces both salivary and serum antibody responses
50. Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus
51. Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge
52. Safety and immunogenicity in volunteers of a new candidate mucosal adjuvant, LT(R192G)
53. The adjuvant effect of a non-toxic mutant of heat-labile enterotoxin of Escherichia coli for the induction of measles virus-specific CTL responses after intranasal co-immunization with a synthetic peptide
54. Probing the structure-activity relationship of Escherichia coli LT-A by site-directed mutagenesis
55. A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity. PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins
56. Recombinant adenoviruses as vectors for mucosal immunity
57. Salmonellae as oral vaccine carriers
58. Refined structure of Escherichia coli heat-labile enterotoxin, a close relative of cholera toxin
59. Crystal structure of a cholera toxin-related heat-labile enterotoxin from E. coli
60. Immune stimulating complexes as mucosal vaccines
61. Mucosal immunity to HIV-1: Systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A)
62. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato
63. Safety and enhanced immunogenicity in volunteers of an oral, inactivated, whole cell Campylobacter vaccine co-administered with a modified E. coli heat-labile enterotoxin adjuvant, LT (R192G)
64. A single amino acid substitution in the A subunit of Escherichia coli enterotoxin results in loss of its toxic activitiy
65. Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection
66. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae
67. Helper Thl and Th2 cell responses following mucosal or systemic immunization with cholera toxin
68. Helper T cell subsets for immunoglobulin A responses: Oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosal associated tissues
69. The role of Th1 and Th2 cells for mucosal lgA responses
70. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity
71. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity